Safety Shot, Inc. (Nasdaq: SHOT) is expected to list on 2026-07-17, but the price range has not been disclosed. The company is already public, so the current filing is a resale/shelf setup rather than a fresh IPO. The bull case is a differentiated functional beverage with early revenue growth; the bear case is tiny sales, heavy losses, and dilution risk.
Safety Shot, Inc. (Nasdaq: SHOT) is expected to list on 2026-07-17, but the price range has not been disclosed. The company is already public, so the current filing is a resale/shelf setup rather than a fresh IPO. The bull case is a differentiated functional beverage with early revenue growth; the bear case is tiny sales, heavy losses, and dilution risk.
Quick Facts
Expected listing date: July 17, 2026
Exchange: NASDAQ
Proposed symbol: SHOT
Status: Expected
Company Overview
Safety Shot, Inc. is a consumer packaged goods company operating in the functional beverage and dietary supplement space. In its SEC filings, the company says it acquired the assets of GBB Drink Lab in August 2023, changed its name to Safety Shot, Inc., and launched e-commerce sales in December 2023. The core product is a 12-ounce beverage designed to reduce the accumulation of blood alcohol, and the company has also introduced a powdered stick pack and a 4-ounce version. It says the formulation includes 28 active ingredients, all GRAS.
The company’s investor site says the brand launched in Q4 2023 and was rebranded as Sure Shot in Q4 2024. It is headquartered in Scottsdale, Arizona. The business is still very small in revenue terms, but it is trying to carve out a niche in a category that blends functional wellness, hydration, and alcohol-related recovery. The broader market is fragmented: the company cites a hangover-remedy market of about $1.5 billion growing at 14.6% CAGR through 2028, while adjacent sleep-related supplements are a much larger category with a cited $6.8 billion market and 5.1% CAGR to 2034. That gives Safety Shot a real consumer-wellness tailwind, but it also means it is competing in a crowded, claim-sensitive niche.
Why They're Going Public
This is not a traditional primary IPO raise. The April 2025 S-1 is a resale registration statement, so the company is not selling a new block of shares to fund operations through this filing. The document says Safety Shot would receive proceeds only if certain warrants are exercised, with approximately $2.32 million possible if all Bigger Warrants are exercised, and those proceeds would be used for general working capital.
Going public, or staying public through these follow-on filings, gives Safety Shot access to capital markets and liquidity for existing holders, while also helping it keep financing flexibility in a business that has already relied on notes, warrants, and settlement agreements. For a company with limited cash and a small revenue base, that flexibility matters more than a one-time IPO cash infusion.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Safety Shot’s top line is growing, but from a very small base. In 2024, the company reported sales of $701,967 versus $202,670 in 2023, which works out to about 246% year-over-year growth. That is a strong growth rate, but the absolute revenue level is still tiny for a public consumer brand. The company also reported cost of sales of $3,147,724 in 2024, which was far above revenue and produced a gross loss of $2,445,757.
Profitability remains the central issue. Safety Shot posted a net loss of $49,409,632 in 2024, compared with a net loss of $15,083,041 in 2023. Cash and cash equivalents were $348,816 at year-end 2024, up from $124,214 at year-end 2023, which is not much cushion relative to the loss profile. The company does not disclose customer count, but it does disclose concentration: in 2024, two customers represented 39% and 4% of total revenues, and in 2023, two customers represented 59% and 11% of total revenues. That makes the revenue base look early-stage and uneven, even with the growth rate.
Risk Factors
The biggest risk is that Safety Shot is still operating at a very early commercial scale while burning a large amount of capital. Revenue of $701,967 does not yet support the cost structure, and the company’s $49.4 million net loss shows how far it is from sustainable profitability. Customer concentration adds another layer of fragility, because a small number of buyers accounted for a large share of sales in both 2024 and 2023.
Regulatory and financing risks are just as important. The product is marketed in the dietary supplement space, so FDA and DSHEA-related compliance matters. The company also says its proprietary formulations and IP may not be fully protected. On the capital side, Safety Shot has multiple convertible notes, warrants, and settlement agreements that can create dilution, and Nasdaq sent a notice in January 2025 after the stock traded below $1.00 for 30 consecutive days. That combination makes the equity story highly sensitive to financing terms, share count changes, and continued listing compliance.
Comparable Public Companies
The closest public comps are imperfect, but they help frame the market. Coca-Cola (KO) and PepsiCo (PEP) are the broad beverage incumbents, while Monster Beverage (MNST) is the more relevant functional beverage peer. Constellation Brands (STZ) is alcohol-adjacent and useful for sentiment context, and Boston Beer (SAM) shows how investors can value branded beverage innovation when growth is uneven. Safety Shot is much smaller than all of them and has far less operating history, so it should be viewed as a micro-cap consumer wellness story rather than a mainstream beverage peer.
The comp set is trading in a mixed environment. KO and PEP have been roughly flat to modestly up or down over the last 6 to 12 months and generally trade around high-teens to mid-to-high-teens P/E multiples. MNST tends to command a premium P/E, while STZ has been down or range-bound and SAM has been volatile. That tells you the sector is not in a euphoric IPO window; it is a selective market that rewards scale, margin durability, and brand strength. Safety Shot does not yet have those traits, so any valuation will likely hinge on the market’s appetite for a speculative functional-beverage narrative.
Verdict
The setup favors a watchlist approach as this namesake listing date approaches. Because the company has not disclosed a price range or share count, the key question is not just demand, but whether the market is willing to underwrite a tiny-revenue, high-loss consumer brand with meaningful dilution overhang. Shareholders should watch the final capital structure, any warrant exercise dynamics, and whether the company can show even modest traction beyond the early e-commerce launch phase.
The timing angle is that Safety Shot is trying to tap a niche wellness and functional-beverage theme at a moment when investors are still willing to look at differentiated consumer products, but only selectively. This is not a broad IPO-market momentum story; it is a narrow, claim-driven category play with a first-mover pitch around blood-alcohol reduction. That makes it noteworthy, but also makes execution, regulatory discipline, and financing terms the real story as it prices.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
